Healthy Subjects Clinical Trial
Official title:
Quantitative Sensory Testing, Physical Activity, and Body Composition in Adults
The purpose of this study is to investigate the influence of baseline experimental pain sensitivity and expectation on the pain response following a single exercise session. Pain assessment will be done with different intensities of noxious stimuli. In addition, the expectation of how exercise impacts pain will be studied.
Status | Recruiting |
Enrollment | 250 |
Est. completion date | December 30, 2022 |
Est. primary completion date | December 30, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Healthy adults - English proficiency Exclusion Criteria: - Acute pain condition - Chronic pain condition - Mental health disorder - Cardiovascular disease - Any chronic illness - Difficulty with physical exercise - Recent surgery - Pulmonary disease - Diabetes - Smoking - Raynaud disease - Claustrophobia |
Country | Name | City | State |
---|---|---|---|
United States | Marquette University | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Marquette University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change from baseline of pain ratings during temporal summation of pressure pain assessment | Temporal summation is the increase of pain over time caused by a constant or repetitive noxious stimulus. Pain reports will be obtained during the application of constant mechanical stimulus with various intensities. Subjects will be asked to rate the pain using a numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain). Pain ratings will be obtained at the beginning, during, and at the end of the test while a noxious stimulus is applied to the index finger. The change of pain ratings relative to baseline after exercise or quiet rest will be assessed. | Before and immediately after exercise or quiet rest in session 1 and session 2 which will be on day 1 and day 7 of data collection. | |
Secondary | Expectation | Subjects will be asked about their expectation of whether exercise will increase, decrease, or have no effect on the pain. | Before exercise which will be on day 1 and day 7 of data collection. | |
Secondary | State version of the State-Trait Anxiety Inventory (STAI) | A 20-item questionnaire from state-trait anxiety inventory that evaluates different feelings the subject may or may not have at the moment. The score of the questionnaire ranges from 0 to 80. Higher scores indicate greater state anxiety levels. | After each temporal summation protocol in the first and second session which are on day 1 and day 7 of data collection. | |
Secondary | Trait version of the State-Trait Anxiety Inventory (STAI) | A 20-item questionnaire from state-trait anxiety inventory that evaluates how the subject feels in general and not restricted to the current moment. The score of the questionnaire ranges from 0 to 80. Higher scores indicate greater trait anxiety levels. | Baseline (beginning of session 1) which is day 1 of the data collection. | |
Secondary | Pain catastrophizing scale | A 13-item scale that evaluates if the subject has an exaggerated negative mental set towards pain. It has 3 sub-scales which are magnification, rumination, and helplessness. The scores of the sub-scales are summed to get the total score. The total score ranges from 0 to 52. Greater scores indicate greater catastrophizing thinking. | Baseline (beginning of session 1) which is day 1 of the data collection. | |
Secondary | Situational pain catastrophizing scale | A 6-item questionnaire that explores the negative mental set or catastrophizing thinking in reference to a particular experimental pain experience (i.e., temporal summation protocol). The score ranges from 0 to 24 with higher scores indicating greater situational catastrophizing. | After each temporal summation protocol in the first and second session which are day 1 and day 7 of data collection. | |
Secondary | Physical activity assessment using International physical activity questionnaire. | International physical activity questionnaire (IPAQ) will be used to assess physical activity in the past week. IPAQ evaluates physical activity not only related to leisure time but also related to other domains such as transportation, work, gardening or house related physical activities. The questionnaire has been shown to be reliable and valid. The time spent in moderate to vigorous physical activity (minutes/ week) from every domain will be summed with 0 indicating no time (minutes / week) spent moderate to vigorous activities and higher values indicate greater time spent in moderate to vigorous physical activity. | Baseline (beginning of session 1 or 2) which is either day 1 or day 7 of data collection. | |
Secondary | Muscle mass assessment using Dual-energy x-ray absorptiometry. | Dual-energy x-ray absorptiometry (General Electric Healthcare, Madison, Wisconsin) is an x-ray scan that is used to assess muscle mass. | Baseline (in the first or second session) which is either day 1 or day 7 of data collection. | |
Secondary | Fat mass assessment using Dual-energy x-ray absorptiometry. | Dual-energy x-ray absorptiometry (General Electric Healthcare, Madison, Wisconsin) is an x-ray scan that is used to assess fat mass. | Baseline (in the first or second session) which is either day 1 or day 7 of data collection. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |